Pelvic lymphadenectomy for staging clinically localized prostate cancer. Indications, complications, and results in 217 cases.
We reviewed the findings of 217 consecutive pelvic lymphadenectomies performed in patients with clinically localized prostatic carcinoma focusing particular attention on the importance of completely removing the hypogastric lymph nodes and on the operative complications associated with a more extensive dissection. Metastatic disease was identified in the lymph nodes of 127 patients (58.6%). The hypogastric nodes were involved in two thirds of the patients with lymph node metastases, and in 29 percent the hypogastric nodes were the only site of metastasis. No increased operative morbidity was documented as a result of extending the level of the pelvic lymphadenectomy to include the lower hypogastric nodes. We conclude that although the lower hypogastric lymph nodes have not been routinely included in most pelvic lymphadenectomies, their removal is important in detecting metastases.
McDowell
G C
GC
Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston.
Johnson
J W
JW
Tenney
D M
DM
Johnson
D E
DE
D000230:Adenocarcinoma / Q000473:pathology* / Q000556:secondary / Q000628:therapy; D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D006801:Humans; D008197:Lymph Node Excision / Q000009:adverse effects; D008198:Lymph Nodes / Q000473:pathology* / Q000601:surgery; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010388:Pelvis; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000628:therapy